Market Place
Sourcing Support
Veru to Present at Sarcopenia & Wasting Disorders Conference
26 Nov 2024 //
GLOBENEWSWIRE
Veru Reports Meta-analysis Supporting Enobosarm for Weight Loss
05 Nov 2024 //
GLOBENEWSWIRE
Veru Presents Analysis Supporting Enobosarm For Weight Loss At ObesityWeek
21 Oct 2024 //
GLOBENEWSWIRE
Veru Keynote On Enobosarm And GLP-1 Agonist For Weight Loss
16 Oct 2024 //
GLOBENEWSWIRE
Veru to Present at the 2024 Cantor Global Healthcare Conference
11 Sep 2024 //
GLOBENEWSWIRE
Veru Reports Q3 2024 Results And Full Enrollment For QUALITY Study
08 Aug 2024 //
GLOBENEWSWIRE
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
01 Aug 2024 //
GLOBENEWSWIRE
Veru to Participate in the BTIG Virtual Biotechnology Conference
29 Jul 2024 //
GLOBENEWSWIRE
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
02 Jul 2024 //
GLOBENEWSWIRE
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
18 Jun 2024 //
GLOBENEWSWIRE
Veru Reminds Shareholders To Vote Before Deadline For 2024 Annual Meeting
17 Jun 2024 //
GLOBENEWSWIRE
Veru to Present at the American Diabetes Association`s 84th Scientific Sessions
10 Jun 2024 //
GLOBENEWSWIRE
Veru to Present at the Jefferies Global Healthcare Conference
22 May 2024 //
GLOBENEWSWIRE
Veru Names Steven Heymsfield Principal Investigator For Enobosarm Trial
15 May 2024 //
GLOBENEWSWIRE
Veru Announces Mitchell Steiner As Biomed Israel 2024 Keynote Speaker
14 May 2024 //
GLOBENEWSWIRE
Veru Fiscal Q2 2024 Results, Enobosarm Weight Loss Program
08 May 2024 //
GLOBENEWSWIRE
Veru to Present at the GLP-1 Based Therapeutics Summit
02 May 2024 //
GLOBENEWSWIRE
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
01 May 2024 //
GLOBENEWSWIRE
Veru Enrolls First Patients In Enobosarm-Semaglutide Weight Loss Trial
30 Apr 2024 //
GLOBENEWSWIRE
Veru Presents at AACE 2024 Annual Meeting
25 Apr 2024 //
GLOBENEWSWIRE
Veru Announces Date of 2024 Annual Meeting of Shareholders
01 Apr 2024 //
GLOBENEWSWIRE
Veru Reschedules Annual Meeting of Shareholders
22 Mar 2024 //
GLOBENEWSWIRE
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor
12 Mar 2024 //
GLOBENEWSWIRE
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report
27 Feb 2024 //
GLOBENEWSWIRE
Veru Announces New Scientific Advisory Board for its Enobosarm Program
20 Feb 2024 //
GLOBENEWSWIRE
Veru Reports Fiscal 2024 First Quarter Financial Highlights
08 Feb 2024 //
GLOBENEWSWIRE
Veru needs cash for fresh trial of respiratory distress drug
08 Feb 2024 //
FIERCE BIOTECH
Veru Announces FDA Clearance of IND Application to Initiate Ph 2b with Enobosarm
06 Feb 2024 //
GLOBENEWSWIRE
Veru to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
31 Jan 2024 //
GLOBENEWSWIRE
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
25 Jan 2024 //
GLOBENEWSWIRE
Veru Submits IND Application to FDA for the Development of Enobosarm
08 Jan 2024 //
GLOBENEWSWIRE
Veru to Host Investor Call on January 4th, 2024
19 Dec 2023 //
GLOBENEWSWIRE
Veru Announces Pricing of Public Offering of Common Stock
14 Dec 2023 //
GLOBENEWSWIRE
Veru Announces Proposed Public Offering of Common Stock
13 Dec 2023 //
GLOBENEWSWIRE
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm
04 Oct 2023 //
GLOBENEWSWIRE
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin
26 Sep 2023 //
GLOBENEWSWIRE
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Conference
20 Sep 2023 //
GLOBENEWSWIRE
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm
11 Sep 2023 //
GLOBENEWSWIRE
Veru to Present at the H.C. Wainwright 25th Annual Global Investment
30 Aug 2023 //
GLOBENEWSWIRE
Veru Reports Fiscal 2023 Third Quarter Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
03 Aug 2023 //
GLOBENEWSWIRE
Veru Inc.™s Oncology Drug Research Program Partner, The University
21 Jun 2023 //
GLOBENEWSWIRE
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley
01 Jun 2023 //
GLOBENEWSWIRE
Veru to Present at the Jefferies Healthcare Conference
24 May 2023 //
GLOBENEWSWIRE
Veru Reports Fiscal 2023 Second Quarter Financial Results
11 May 2023 //
GLOBENEWSWIRE
Veru Reaches Agreement with FDA on Confirmatory pH 3 Trial for Sabizabulin
04 May 2023 //
GLOBENEWSWIRE
Veru Enters into Common Stock Purchase Agreement for Up to $100 M
03 May 2023 //
GLOBENEWSWIRE
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
27 Apr 2023 //
GLOBENEWSWIRE
Veru Sells ENTADFI® Business for $20 Million Plus
20 Apr 2023 //
GLOBENEWSWIRE
Veru sells combo prostate drug to Blue Water for up to $100M
20 Apr 2023 //
FIERCE PHARMA
Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million
20 Apr 2023 //
PRESS RELEASE
Veru Enters Into Supply Agreement with Afaxys to Expand to FC2 Female Condom
19 Apr 2023 //
GLOBENEWSWIRE
Veru Enters Into Agreement with Afaxys to Expand Access to FC2 Female Condom
19 Apr 2023 //
PRESS RELEASE
Veru Announces Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
11 Apr 2023 //
GLOBENEWSWIRE
Veru Announces Preclinical Results from Expanded Sabizabulin Program
04 Apr 2023 //
GLOBENEWSWIRE
Veru to proceed with late-stage study of COVID pill despite FDA snub
14 Mar 2023 //
REUTERS
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
FDA rejects Covid-19 drug over uncertainties around small trial
04 Mar 2023 //
ENDPTS
Veru Provides FDA Update on Request for EUA for Sabizabulin
03 Mar 2023 //
PRESS RELEASE
Veru Reports Fiscal 2023 First Quarter Financial Results
09 Feb 2023 //
GLOBENEWSWIRE
